(KOD) – PRNewswire
-
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
-
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
-
Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting
-
Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
-
Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights
-
Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulator
-
KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL
-
Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society
-
Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
-
New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein oc
-
Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights
-
Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab D
-
Kodiak Sciences to Present at Upcoming Investor Conferences
-
Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights
-
Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting
-
Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases
-
Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
-
Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 20
-
Kodiak Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Kodiak Sciences to Present at the Evercore ISI 5th Annual HealthCONx Conference
-
Kodiak Sciences Announces Third Quarter 2022 Financial Results and Recent Business Highlights
-
Kodiak Sciences to Present at the 2022 Morgan Stanley Healthcare Conference
-
Kodiak Sciences Announces Upcoming Presentations of Tarcocimab Tedromer (KSI-301) Phase 3 BEACON Study Results in Retinal Vein Occlusion (RVO)
-
Kodiak Sciences Announces Second Quarter 2022 Financial Results and Recent Business Highlights
-
Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion
-
Kodiak Sciences Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy
-
Kodiak Sciences to Present at the Jefferies Global Healthcare Conference
-
Grand Opening of Kodiak Sciences' Purpose-built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal Diseases
-
Kodiak Sciences Announces First Quarter 2022 Financial Results and Recent Business Highlights
-
Kodiak Sciences Announces Presentation of KSI-301 Phase 2b/3 Study Data in wet AMD at Upcoming Research Conferences
-
Kodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
-
Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration
-
Kodiak Sciences Completes Enrollment in GLEAM and GLIMMER Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema
-
Kodiak Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
-
Kodiak Sciences Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein Occlusion
-
Kodiak Sciences Announces Third Quarter 2021 Financial Results and Recent Business Highlights
-
Kodiak Sciences to Present at Upcoming Conferences
-
Kodiak Sciences Announces New Long-Term Performance Incentive Plan
-
Kodiak Sciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
-
Kodiak Sciences Announces Second Quarter 2021 Financial Results and Recent Business Highlights
-
Kodiak Sciences to Present at Upcoming Conferences
-
Kodiak Sciences Announces First Quarter 2021 Financial Results and Recent Business Highlights
-
Kodiak Sciences to Present at Upcoming Conferences
-
Kodiak Sciences to Present at Upcoming Conferences
-
Kodiak Sciences Announces Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
-
Kodiak Sciences Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal V
-
Kodiak Sciences Announces Upcoming Presentation of KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition
-
Kodiak Sciences to Present at the J.P. Morgan Healthcare Conference
-
Kodiak Sciences Announces Closing of $645.0 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Back to KOD Stock Lookup
